FY 2024: Record Revenues of $27.6 Million; Gross Margin 48.4%; Record EBITDA of $6.3 MillionQ4 2024: Revenues of $6.3 Million; EBITDA of $1.7 Million TEL AVIV, Israel, April 28, 2025 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, today reported results for the twelve months and fourth quarter, ended December 31, 2024.

Anthony Rendon, former Speaker of the House for the State of California, and Lou Martinez, the current Mayor of Hanford, CA, where FF’s Manufacturing facility is located, both offered congratulatory messages to YT as well as their unwavering support for FF during this major transformation period for the Company.

BEIJING, April 28, 2025 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S.-listed EV charging service company in China, today announces that the previously announced change of the ratio (the "ADS Ratio") of its American depositary shares (the "ADSs") to its Class A ordinary shares has taken effect at the open of business on April 28, 2025 (U.S. Eastern Time) ("Effective Date").

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This represents the third clinical study evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting, with outcomes reported in mismatch repair–proficient (pMMR/MSS) and mismatch repair–deficient (dMMR/MSI-H) solid tumors. These findings include the first reported outcomes with BOT/BAL outside colorectal cancer in the neoadjuvant setting.